Closing the loop on type 1 diabetes – Therapeutic development whitepaper

Fluicell’s type 1 diabetes development program is aimed at creating patient-tailored artificial pancreatic islets capable of enabling glycemic control. Today, we present a new whitepaper describing our development program and goals, the need for improved treatment options and the market and socioeconomic value of new treatments based on cell therapy.

“We offer a unique capacity to construct artificial pancreatic islets, which have the potential to be a real game changer for the treatment of type 1 diabetes. To really develop how we treat diabetes and to address the major impact the disease has on individuals and society, we need to go beyond what is possible with existing treatments. Cell-based therapies that can replicate the full endocrine function of the pancreas are seen by many in the field as the most promising option for achieving this – and this is exactly what we believe we have the potential to do. Fluicell’s vision and ultimate goal is to provide a curative solution for type 1 diabetes”, comments Victoire Viannay, CEO of Fluicell.

Type 1 diabetes is a growing medical problem with an estimated global annual cost of $90 billion. Existing insulin-based treatments do not provide adequate care and patients with type 1 diabetes still experience a significant impact on health and well-being. Fluicell is engaged in the development of artificial pancreatic islets with the aim of replacing the pancreas’ own glycemic control function, without the need for immunosuppressive drugs. The type of treatment that Fluicell is developing is estimated to bring cost savings of over $28 billion annually, in the US alone.

“Our research in regenerative medicine aims to create bioprinted tissues with the capacity to promote organ repair or to replace lost functionality. With this as a foundation, Fluicell uses the precise tissue-generating capabilities of our Biopixlar bioprinting platform to construct artificial islets for the treatment of type 1 diabetes. We have made significant progress in the discovery phase and have reached important milestones in terms of functionality and production capabilities. We continue to make further functional improvements as we prepare to move on to preclinical proof of concept development, which we aim to start in 2024 in collaboration with an academic partner”, concludes Victoire Viannay.

Share this article: